 MINNEAPOLIS, MN ACCESSWIRE July 1, 2020 Celcuity Inc. CELC, a clinical-stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that it will host a call to discuss its CELsignia pathway activity test for ovarian cancer on Monday, July 13, 2020 at 1:00 pm Eastern Time. The call will feature a presentation by Celcuitys management team including CEO and Co-Founder, Brian Sullivan and Chief Scientific Officer and Co-Founder, Lance Laing, Ph.D. They will provide a corporate overview and an update on their 3rd Generation diagnostic platform including recent data presented at AACR for their first CELsignia Pathway Activity Test for ovarian cancer. The studies presented in the AACR e-poster characterize signaling activity in ovarian patient tumor cells and ovarian tumor cell lines and evaluate the oncogenicity of coincident abnormal HER2 and c-Met signaling in ovarian cancer tumors using an animal model. 